M itral valve intervention in heavy mitral annular calcification (MAC) presents significant surgical challenges. Current dedicated transcatheter mitral valve therapy excludes patients with significant MAC. Transcatheter aortic valve implantation devices have been used for mitral valve-in-valve and valve-in-ring procedures. 1 Balloon-expandable valves have been used with some success in the presence of MAC, but their use is limited by the inability to reposition if left ventricular outflow tract (LVOT) obstruction occurs. 2 We describe 2 cases, where a self-expanding and repositionable transcatheter valve was implanted in the mitral position using MAC as an anchor.
Case 1
A 75-year-old woman presented with increasing breathlessness after her aortic valve replacement and mitral valve repair in 2014. Echocardiography demonstrated a functioning prosthetic aortic valve and severe mitral regurgitation. The mitral annulus had a measured perimeter of 77 mm and area of 400 mm 2 (transesophageal echocardiography) with an aortomitral annular angle of 124° (computed tomography).
Case 2
A 62-year-old man presented with New York Heart Association III symptoms. Medical history included Alport syndrome, transcatheter aortic valve implantation (26 mm Sapien XT), and permanent pacemaker. Echocardiography demonstrated a functioning prosthetic aortic valve and severe mitral regurgitation. The mitral annulus had a measured perimeter of 82 mm and area of 440 mm 2 (transesophageal echocardiography) with an aortomitral annular angle of 140° (computed tomography).
Procedure
In both cases, preprocedural multimodality imaging was crucial to assessment of feasibility (Figures 1 and 2 ). The procedure was performed via transapical access. The mitral valve was crossed with a multipurpose catheter and exchanged for a SAFARI wire. The procedure was guided by fluoroscopy (initial device placement) and transesophageal echocardiography (assessment of valve function and LVOT obstruction). In the first case, the valve was resheathed after 60% deployment to optimize final position.
In both cases, the LOTUS valve system was deployed with a good waist, excellent hemodynamic performance, and no LVOT obstruction (Figures 3-5 ). The mean transvalvular gradients were 4 and 7 mm Hg, respectively, with no more than mild paravalvular regurgitation. After a period of recovery with no postprocedural complications, both patients were discharged home on day 6 on warfarin.
Discussion
The treatment of degenerative native mitral valve disease is feasible with balloon-expandable transcatheter aortic valve implantation devices. However, this has been associated with LVOT obstruction, embolization/migration, 3 and annular damage. 4 These potential disadvantages may be overcome by the use of a self-expandable and repositionable device. LVOT obstruction and security of fixation can be assessed once optimal positioning has been achieved. Gradual implantation can also minimize the risk of annular damage (despite deliberate oversizing).
The accuracy of mitral annular sizing and assessment of the potential risk of LVOT obstruction will only improve with more experience. Meanwhile, these initial cases indicate the feasibility and effectiveness of transcatheter mitral valve implantation in MAC using a fully repositionable and self-expanding valve. Similar success has also been reported with the Direct Flow Medical aortic. 5 Subject to careful preprocedural anatomic assessment (annular sizing, aortomitral annular, and LV cavity dimensions), this novel approach may prove an effective treatment option for highly selected patients who would otherwise be declined intervention. 
